Objectives-The number of endothelial progenitor cells (EPCs) that can be obtained from adult bone marrow and peripheral blood to treat cardiovascular diseases is limited. The goal was to examine the endothelial potential of Wharton jelly in human umbilical cord (WJC)-derived stem cells and evaluate their potential to affect neointimal formation after vascular injury. Methods and Results-Mesenchymal cells (MCs) were isolated from WJC and cultured in endothelial growth medium.
D isruption of the anatomic and functional integrity of the endothelium has been postulated as the major mechanism for the initiation of atherosclerosis and restenosis. 1 A corollary hypothesis is that restoration of endothelial integrity should inhibit these diseases. Unfortunately, mature endothelial cells have limited proliferative capacity, which makes it necessary to search for alternative sources of these cells for autologous or allogenic use. In this regard, transplantation of autologous endothelial progenitor cells (EPCs) may be a feasible adjunctive therapeutic option for accelerated reendothelialization of vessels and grafts injured during revascularization procedures and for the prevention of neointimal hyperplasia. Preliminary clinical studies have suggested that infusion of human blood-derived EPCs may improve acute myocardial infarction 2 and that infusion of crude bone marrow mononuclear cells may improve limb ischemia in patients with peripheral arterial disease. 3 However, the clinical use of bone marrow mesenchymal stem cells (MSCs) has presented problems, including pain, morbidity, and a decline in the number and plasticity of these cells with aging and age-related diseases. 4 This has led many researchers to investigate alternative sources of MSCs. The two new options are the umbilical cord blood (CB) and the Wharton jelly in umbilical cord. CB has many advantages of low incidence of graft versus host disease, prompt availability, reduced risk of transmitting infections, and no risk to donors. However, limited cell dose has been the major limitation to the wide use of CB for allogeneic transplantation. 5 Wharton jelly, a mu-cous tissue, is composed of stromal cells and extracellular matrix within the umbilical cord. Recent reports have identified it as a novel source of multipotent stem cells; these cells display a fibroblast-like morphology, express mesenchymal markers, and have the potential to differentiate into osteogenic, adipogenic, chondrogenic, and cardiogenic cells, as well as dopaminergic neurons. 6 -8 These findings may have a significant impact on the study of early human endothelial differentiation, functional genomics, pharmacological testing, cell therapy, and tissue engineering by helping to eliminate worrying ethical and technical issues.
Pigment epithelium-derived factor (PEDF) is a secreted glycoprotein that was first identified as a neurotrophic factor purified from conditioned medium from cultured retinal pigment epithelial cells. 9 Expression of PEDF by endothelial cells is essential for the inhibition of proliferation and migration of smooth muscle cells (SMCs) after balloon injury. 10 PEDF blocks TNF-␣-induced endothelial cell activation by its antioxidative properties. 11 These observations suggest that PEDF might have beneficial effects on atherosclerosis by suppressing inflammatory proliferative responses to injuries. However, the role of PEDF produced by EPCs, which may be considered for augmenting collateral vessel growth to ischemic tissue, 12 remains to be elucidated during restenosis after angioplasty. In the present study, we described a streamlined method for the rapid isolation, growth, and ex vivo expansion of late outgrowth endothelial cells (WJC-OECs) from Wharton jelly of human umbilical cord and evaluated the ability of these cells to reendothelialize, and inhibit neointimal hyperplasia in injured femoral arteries of mice. We also examined the direct effects of WJC-OECconditioned medium on the migration and proliferation of human aortic smooth muscle cells (HASMCs) and the role of PEDF in these effects. Our results showed that WJC-OEC transplantation led to rapid reendothelialization of denuded arteries, resulting in significant inhibition of neointimal thickening. To our knowledge, this is first report that WJC-OECs derived from umbilical cord help accelerate reendothelialization and attenuate vascular remodeling at sites of arterial injury and these effects were closely associated with PEDF.
Methods
An expanded Materials and Methods section is described in detail in supplemental materials (available online at http://atvb. ahajournals.org).
Induction of Cell Differentiation
Institutional review board approval was obtained for all procedures. Mesenchymal cells (MCs) were obtained from fresh human umbilical cords. Half of the cells were maintained in endothelial basal growth medium (EBM-2, Cambrex, BioScience) supplemented with 20% fetal bovine serum (FBS). The control cells were maintained in DMEM supplemented with 10% FBS and 4.5 g/L glucose.
SMC Migration and Proliferation Assays
To examine the effect of conditioned medium collected from OECs on the migration and proliferation of HASMCs, the modified Boyden chamber assay and BrdU incorporation assay were used.
Results

Characterization of OECs Produced by the Differentiation of MCs in WJC and CB
MCs were extracted from Wharton jelly by collagenase digest. When plated and cultured in DMEM supplemented with glucose and 10% FBS, these cells had a fibroblast-like phenotype at 3 days after plating (supplemental Figure IA) , then, after 7 to 10 days, they became confluent and grew as a whirlpool (supplemental Figure IB) . To investigate the potential of umbilical cord MCs to differentiate into endothelial cells, the pelleted cells after centrifugation of freshly prepared tissue pieces were cultured in EGM-2 medium. Under these culture conditions, some colonies of EPCs, with a center of densely packed round cells and a periphery of seemingly mature and elongated cells, were seen at day 7 (supplemental Figure IC) . After 2 weeks, many EPC colonies were present and the cells showed the cobblestone-like morphology characteristic of an endothelial cell monolayer (supplemental Figure ID) . These cells were capable of taking up LDL particles from the medium (supplemental Figure IE ) and were assembled into primitive vascular tube-like structures when plated in Matrigel (supplemental Figure IG) . In contrast, MCs did not show the phenomena (supplemental Figure IF and IH). When OEC characterization was further performed by immunostaining, the majority of the cells expressed the EPC markers CD34 and KDR, and the mature endothelial markers vWF, CD31, and TM. Confocal microscopy showed that these 3 markers were clearly more strongly expressed by the differentiated cells than controls ( Figure  1A ). Flow cytometric analysis ( Figure 1B ) and Western blotting ( Figure 1C ) confirmed that the cells expressed high levels of all 5 markers. The OECs showed less expression of the early hematopoietic stem-cell marker CD133 than MCs. Both of OECs and MCs did not express CD45, the leukocyte common antigen.
The endothelial phenotypes of OECs derived from CB were similar to those of WJC (supplemental Figures II, III, IV). Furthermore, there was a 2.0-fold increase in the number of the colony-forming units and a 2.4-fold decrease in the population-doubling times of WJC-OECs compared with CB-OECs ( Figure 1D and 1E ). Based on the clonogenic and proliferative potential, WJC-OECs were better than CB-OECs.
WJC-OECs Inhibit Neointimal Hyperplasia in the Spring Wire-Injured Femoral Artery
To determine whether these WJC-OECs migrated to the injured site and participated in the reendothelialization of endothelial denuded artery in vivo, cultured WJC-OECs, CB-OECs, or MCs were injected into the tail vein after endothelial denudation by spring wire treatment. A lot of CM-DiI-labeled WJC-OECs were seen in the lumen and lining the vascular surface of the injured artery at 4 hours (supplement Figure V Figure VI) . A significant decreased production of IL-␤, an inflammatory cytokine, in the plasma at 4 hours after WJC-OECs transplantation compared with saline, MCs, and CB-OECs-transplanted group (101Ϯ8 versus 450Ϯ10, 412Ϯ15, 380Ϯ20 pg/mL). Femoral arteries at 2 and 4 weeks after the spring wire injury led to the development of a prominent neointima, which was significantly reduced by transplantation of WJC-OECs, but not CB-OECs and MCs ( Figure 3A ). The neointima/media area ratio was significantly reduced at 2 and 4 weeks in the WJC-OEC-seeded vessels compared with saline-treated or MC-or CB-OEC-transplanted vessels ( Figure 3B group was consistently observed, although the decrease did not reach statistical significance compared with saline-treated group. Staining for vWF confirmed the endothelial phenotype of the transplanted cells and revealed the integrity of the newly formed endothelial monolayer in the WJC-OECseeded vessels ( Figure 3C ).
OEC-Conditioned Medium Attenuates SMC Migration In Vitro
The cytokine PEDF is known to affect the migration of SMCs. 10 To investigate the mechanisms by which OECs caused a reduction in neointimal hyperplasia, we examined PEDF expression in the vascular wall and found higher expression of PEDF in ECs not in SMCs, stained for ␣-actin, in the WJC-OEC-transplanted group than the CB-OEC-and the MC-transplanted group ( Figure 3C ). The transplantation of WJC-OECs transfected with PEDF-specific siRNA did not reduce neointimal hyperplasia (Figure 3 ). In addition, we measured PEDF levels in the different conditioned media by ELISA and found they were significantly higher in WJC-OECconditioned medium (WJC-OEC-CM) than in MC-, CB-, and WJC-OEC/siPEDF-CM (1.8Ϯ0.1 versus 1.2Ϯ0.1, 1.0Ϯ0.2, 1.1Ϯ0.2 ng/mL). Similar results were confirmed by immunostaining and Western blotting (supplemental Figure VII) .
To examine in detail the role of WJC-OEC-CM and PEDF in neointimal hyperplasia, an in vitro model of SMC wound repair was used. As shown in supplemental Figure VIIIA , the number of cells that migrated into the wounded area was increased by M231-SMGS, MC-FM, and OEC-FM. MC-CM did not affect the induced migration of SMC by MC-FM treatment, but WJC-OEC-CM or CB-OEC-CM reduced SMC migration when compared with OEC-FM. The level of the reduced migration by WJC-OEC-CM was higher than that by CB-OEC-CM. In addition, the migration rate of SMCs incubated with WJC-OEC-CM was significantly lower than that in MC-CM, OEC-FM, or CB-OEC-CM ( Figure 4A ). Moreover, the wound closure area/total wound area ratio in WJC-OEC-CM was significantly smaller than that in M231-SMGS, MC-CM, CB-OEC-CM, or OEC-FM ( Figure 4B ). All these effects of WJC-OEC-CM were inhibited by addition of 10 ng/mL anti-PEDF antibody to the cultures and also by conditioned medium from WJC-OECs/PEDFsiRNA ( Figure  4A and 4B) .
A previous study demonstrated that PEDF is important for the migration of VSMCs into the intima. 10 We therefore tested the effect of OEC-CM on cell migration and whether the effect was attributable to PEDF. HASMCs were seeded in the top compartment of the Transwell and different media were added to the lower compartment and the number of transmigrated cells quantified after 8 hour of incubation. As shown in Figure 4C Furthermore, WJC-OEC-CM reduced the wound closure area/total wound area ratio and the migration of HUVECs when compared with that in CB-OEC-CM or in OEC-FM alone (supplemental Figure IX) . These effects were not abolished by addition of anti-PEDF antibody or conditioned medium from PEDF siRNA-transfected WJC-OEC.
OEC-Conditioned Medium Inhibits SMC Proliferation In Vitro
To determine whether OECs inhibited SMC proliferation, HASMCs were incubated for 24 hours with conditioned medium from MCs, WJC-OECs, or CB-OECs, then DNA synthesis was measured. As shown in Figure 5 whereas MC-CM did not show any difference compared with MC-FM. The level of reduction of cell proliferation by WJC-OEC-CM was more than by CB-OEC-CM. Because cell proliferation during exposure to various stimuli is influenced by PEDF, 11 we determined whether the WJC-OEC-CM-reduced proliferation of HASMCs was associated with PEDF using anti-PEDF antibody, and found that it induced a significant increase in BrdU incorporation when compared with WJC-OEC-CM alone. Conditioned medium from PEDF siRNA-transfected WJC-OECs significantly inhibited the reduction of SMC proliferation by WJC-OEC-CM.
In addition, OEC-FM significantly induced the proliferation of endothelial cells, and the effect was not inhibited by WJC-OEC-CM or by CB-OEC-CM (supplemental Figure  XI) . The effects of WJC-OEC-CM plus anti-PEDF antibody or WJC-OEC/siPEDF-CM on EC proliferation also showed no significant difference, when compared with that of WJC-OEC-CM.
Discussion
The unique functional role of endothelial cells in the maintenance of vessel homeostasis makes them prime candidates for cell-based therapy for vascular disease. In this study, we described a simple and cost-effective method for the isolation, culture, and expansion of WJC-OECs that can be induced to differentiate into cells with endothelial cell-like properties. We consistently obtained a sufficient number of WJC-OECs to allow transplantation for in vivo applications within 2 to 3 weeks of initial plating. Furthermore, we clearly showed that these cells could home to sites of injury and significantly reduced the neointimal hyperplasia associated with spring-wire induced injury in mice. We also provided evidence that PEDF was released by the cultured WJC-OECs and that this decreased the migration and proliferation of SMCs.
Although bone marrow and peripheral blood represent the major sources of OECs, the use of cells derived from these sources is not always possible because of the invasive procedures used in aspiration, a high degree of viral infection, and the significant drop in cell numbers and proliferative/ differentiation capacity with age. 4 However, cord blood and umbilical cord can be considered as alternative sources of OECs for experimental and clinical use. CB has many advantages; nonetheless, the number of its nucleated cells is limited and it is considered a seriously weak point in routine application for transplantation. 5 The stromal cells in Wharton jelly, as another source, have been demonstrated to differentiate into chondrogenic, osteogenic, and adipogenic lineages under various culture conditions. 6 -8 Furthermore, these cells have a high proliferation capacity and hemotopoiesissupportive function. 13 In the present study, we investigated the ability of these cells to differentiate into WJC-OECs by treating them with EGM-2 and found that the treatment resulted in expression of the endothelial cell markers. Among these markers, the expression of CD133 was present in endothelial progenitor cells initially isolated from WJC, and then it progressively decreased during differentiation and was scarcely detectable on terminally matured OECs. These results are consistent with previous reports that CD133 is a marker of immature hematopoietic and progenitor cells and is present in few tissues such as placenta, but not detectable on mature endothelium. 14, 15 Our results show that these cells can be easily isolated and expanded in culture and induced to differentiate into WJC-OECs. We also showed that WJC-OECs appear to be superior to CB-OECs based on their clonogenic and proliferative potential. As in a previous report, 16 these findings provide strong evidence for the presence of a cell population within the human umbilical cord that can differentiate into OECs. These cells may therefore prove to be a new source of cells for cell therapies for the repair of stromal tissue and, potentially, the endothelium, thus avoiding the ethical and technical issues involved in the use of cells from other origins.
The regeneration and proliferation of endothelial cells after tissue damage, during neoangiogenesis, or after vascular injury was long believed to be a local process managed by the adjacent endothelial cells within the intact parts of the intima. Although the injury itself may stimulate reendothelialization of the denuded vessel, 17 the time required for this native repair process to restore endothelial function appears be too long to prevent the early critical events leading to activation of vascular SMCs and neointimal hyperplasia. 18 Accordingly, rapid restoration of the endothelial lining and the future ability to engineer EPCs to perform physiological endothelial functions might be a suitable alternative therapy for restenosis. EPCs were initially isolated from bone marrow or peripheral blood and were shown to be used for therapeutic angiogenesis and reendothelialization of engineered tissue grafts. 19 -21 In the present study, histological analyses after cell treatment revealed that the exogenously administered WJC-OECs from umbilical cord were incorporated into the vessel wall predominantly in the lesion area, enhanced reendothelialization at the site, and reduced neointimal hyperplasia. The grafted cells may play an essential role in promoting reendothelialization of the injured vessels by engrafting and releasing chemokines and other mediators that enhance the mobilization and homing of WJC-OECs. The injury may induce expression of G-CSF, MCP-1, SDF-1, and VEGF, which are important in the homing of EPCs. 22, 23 Further studies are needed to identify the cytokines or other factors that cause WJC-OECs to home to the injury site after spring-wire treatment and transplantation of WJC-OECs.
Blockade of SMC proliferation and migration would therefore be a novel therapeutic target for restenosis after angioplasty. 18 In the present study, we first demonstrated that intravenous transfusion of WJC-OECs from umbilical cord reduced neointimal formation after induction of endothelial cell damage, whereas CB-OECs did not have the effect. Despite the broad range of previous work in the application of CB-OECs to ischemia, stroke, and neurological therapy, 24 none of prior studies have addressed the relationships of these cells associated with the vessel-injury model. Based on the present results, WJC-OECs were superior to CB-OECs for the therapy of restenosis because the former possess the extremely strong capacity to inhibit the migration and proliferation of SMCs. A previous study showed a marked improvement in perfusion in the ischemic hind limb of nude mice after muscular transplantation of EPCs from umbilical cord. 16 These findings prove strong support for the use of WJC-OECs as a novel and practical cell-based therapy for vascular disease.
PEDF is a multifunctional factor. 25 PEDF exerts its antiangiogenic activity in human atherosclerotic plaques. 26 Moreover, PEDF plays a protective role against atherosclerosis through its antioxidative properties because it prevents the advanced glycation end product-elicited endothelial nitric oxide synthase reduction 27 and can inhibit occlusive thrombus formation by blocking platelet activation and aggregation. 28 Recently, it has also been shown to strongly inhibit PDEF-induced SMC proliferation and migration by blocking the generation of reactive oxygen species and to block neointimal hyperplasia in balloon-injured rat carotid arteries. 10 In the present study, PEDF levels in WJC-OEC-CM were significantly higher than those in CB-OEC-or in MC-CM. The levels of the wound closure area, transwellfilter migration, and proliferation of SMCs and ECs effected by WJC-OEC-CM were 26Ϯ1 and 63Ϯ2, 47Ϯ2 and 63Ϯ3, 47Ϯ1 and 95Ϯ4%, respectively, compared with OEC-FM. Based on these results, the effects of WJC-OEC-CM on the migration and proliferation of SMCs were significantly higher than those of ECs. These effects of WJC-OEC-CM on those functions of SMCs were abolished by addition of anti-PEDF antibody or by conditioned medium from WJC-OEC with transfection of PEDF siRNA, whereas EC was not. Taken together, the present study demonstrated that the effects of WJC-OECs were mainly on the inhibition of chemotaxis and proliferation of SMCs rather than on those of ECs, and these effects were mediated by the secretion of PEDF from WJC-OECs.
The present study also demonstrated that the vascular wall showed stronger PEDF expression after WJC-OEC transplantation than after CB-OEC or MC transplantation. In addition, we found a significant decreased level of IL-␤, an inflammatory cytokine, in plasma after WJC-OECs transplanted mice compared with saline, MCs, and CB-OEC-transplanted group. The prior studies reported that PEDF suppresses inflammation by modulating macrophage activation 29 and by reducing the proinflammatory cytokine production. 30 As far as we know, this is the first study to demonstrate that PEDF released by WJC-OECs significantly affects SMC migration and proliferation, and may result in decreasing neointimal formation in vivo. Based on the above results it suggests that the production of PEDF from WJC-OECs, not from CB-OECs, plays a protective role against restenosis and may be mediated by antiinflammatory property rather than by antiangiogenic property. However, OECs isolated from cord or adult blood have been used in ischemia, and this cell phenotype has been recently shown to be responsible for formation of new functional vessels surrounded by SMCs, after injection of bone marrow mononuclear cells as a cell therapy product in critical leg ischemia. 31 We cannot exclude the possibility that OECs isolated from WJC, by secreting PEDF, will probably inhibit SMC migration and stabilization of newly formed vessels in a context of ischemia. Further studies are needed to explore the potential clinical impact of WJC-OEC.
In conclusion, the present study describes a simple method for the isolation and expansion of OECs from Wharton jelly and demonstrates that transplantation of these cells not only accelerates reendothelialization, but also profoundly inhibits neointimal hyperplasia after vascular injury. In addition, it shows that these effects are mainly attributable to PEDF. These results suggest that the use of WJC-OECs may be a feasible and efficient therapeutic strategy for the prevention of restenosis after revascularization procedures, such as percutaneous transluminal angioplasty, stenting, and atheroectomy.
